Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder / Logan K. WINK in Journal of Autism and Developmental Disorders, 47-7 (July 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294 Titre : Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.2290-2294 Langues : Anglais (eng) Mots-clés : Autism  Autism spectrum disorder  Metformin  Antipsychotic  Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314 [article] Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder [texte imprimé] / Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur . - p.2290-2294. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294 Mots-clés : Autism  Autism spectrum disorder  Metformin  Antipsychotic  Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314

Brief Report: Telehealth Satisfaction Among Caregivers of Pediatric and Adult Psychology and Psychiatry Patients with Intellectual and Developmental Disability in the Wake of Covid-19 / Victoria ROSEN in Journal of Autism and Developmental Disorders, 52-12 (December 2022)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5253-5265 Titre : Brief Report: Telehealth Satisfaction Among Caregivers of Pediatric and Adult Psychology and Psychiatry Patients with Intellectual and Developmental Disability in the Wake of Covid-19 Type de document : texte imprimé Auteurs : Victoria ROSEN, Auteur ; Elizabeth BLANK, Auteur ; Erica LAMPERT, Auteur ; Kelli C. DOMINICK, Auteur ; Meredith WILL, Auteur ; Craig ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur ; Martine LAMY, Auteur ; Rebecca SHAFFER, Auteur Année de publication : 2022 Article en page(s) : p.5253-5265 Langues : Anglais (eng) Mots-clés : Adult  Humans  Child  covid-19  Pandemics  SARS-CoV-2  Caregivers  Developmental Disabilities/therapy  Personal Satisfaction  Patient Satisfaction  Autism Spectrum Disorder/therapy  Telemedicine/methods  Intellectual Disability  Psychiatry  ASC (autism spectrum conditions)  Developmental disability  Satisfaction  Telehealth  Telepsychiatry Index. décimale : PER Périodiques Résumé : Telehealth has been shown to be both acceptable and effective in many areas of healthcare, yet it was not widely adopted prior to the SARS-CoV-2 (COVID-19) pandemic. Additionally, previous evaluations of telehealth for autism spectrum condition (ASC) and intellectual and developmental disability (IDD) populations are limited in both number and scope. Here, we investigated satisfaction amongst Psychology and Psychiatry patient caregivers at Cincinnati Children's Hospital Medical Center (CCHMC) after the onset of the COVID-19 pandemic. Results (640 responses) showed high rates of satisfaction across departments, appointment types, and diagnoses, with 92% indicating overall satisfaction with their appointment. There were, however, notable decreases in satisfaction among Group Therapy respondents, and those whose diagnosis was classified as Other. En ligne : http://dx.doi.org/10.1007/s10803-022-05712-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489 [article] Brief Report: Telehealth Satisfaction Among Caregivers of Pediatric and Adult Psychology and Psychiatry Patients with Intellectual and Developmental Disability in the Wake of Covid-19 [texte imprimé] / Victoria ROSEN, Auteur ; Elizabeth BLANK, Auteur ; Erica LAMPERT, Auteur ; Kelli C. DOMINICK, Auteur ; Meredith WILL, Auteur ; Craig ERICKSON, Auteur ; Ernest V. PEDAPATI, Auteur ; Martine LAMY, Auteur ; Rebecca SHAFFER, Auteur . - 2022 . - p.5253-5265. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5253-5265 Mots-clés : Adult  Humans  Child  covid-19  Pandemics  SARS-CoV-2  Caregivers  Developmental Disabilities/therapy  Personal Satisfaction  Patient Satisfaction  Autism Spectrum Disorder/therapy  Telemedicine/methods  Intellectual Disability  Psychiatry  ASC (autism spectrum conditions)  Developmental disability  Satisfaction  Telehealth  Telepsychiatry Index. décimale : PER Périodiques Résumé : Telehealth has been shown to be both acceptable and effective in many areas of healthcare, yet it was not widely adopted prior to the SARS-CoV-2 (COVID-19) pandemic. Additionally, previous evaluations of telehealth for autism spectrum condition (ASC) and intellectual and developmental disability (IDD) populations are limited in both number and scope. Here, we investigated satisfaction amongst Psychology and Psychiatry patient caregivers at Cincinnati Children's Hospital Medical Center (CCHMC) after the onset of the COVID-19 pandemic. Results (640 responses) showed high rates of satisfaction across departments, appointment types, and diagnoses, with 92% indicating overall satisfaction with their appointment. There were, however, notable decreases in satisfaction among Group Therapy respondents, and those whose diagnosis was classified as Other. En ligne : http://dx.doi.org/10.1007/s10803-022-05712-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder / Erin HENNEBERRY in Journal of Autism and Developmental Disorders, 51-12 (December 2021)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 51-12 (December 2021) . - p.4370-4394 Titre : Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Erin HENNEBERRY, Auteur ; Martine LAMY, Auteur ; Kelli C. DOMINICK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.4370-4394 Langues : Anglais (eng) Mots-clés : Antipsychotic Agents/therapeutic use  Autism Spectrum Disorder/drug therapy  Autistic Disorder/drug therapy  Humans  Irritable Mood  Psychopharmacology  Anti-psychotic  Autism  Autism spectrum disorder  Drug treatment  Irritability Index. décimale : PER Périodiques Résumé : Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of interfering behavior has progressed in our field, there remain several areas of unmet medical need including most prominently a lack of any approved drug therapies for the core, defining symptoms of autism. We outline the progress to date in the field of autism drug treatment while taking a future look forward into how decades of work can inform better future steps in this field. En ligne : http://dx.doi.org/10.1007/s10803-021-05237-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=454 [article] Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder [texte imprimé] / Erin HENNEBERRY, Auteur ; Martine LAMY, Auteur ; Kelli C. DOMINICK, Auteur ; Craig ERICKSON, Auteur . - p.4370-4394. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 51-12 (December 2021) . - p.4370-4394 Mots-clés : Antipsychotic Agents/therapeutic use  Autism Spectrum Disorder/drug therapy  Autistic Disorder/drug therapy  Humans  Irritable Mood  Psychopharmacology  Anti-psychotic  Autism  Autism spectrum disorder  Drug treatment  Irritability Index. décimale : PER Périodiques Résumé : Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of interfering behavior has progressed in our field, there remain several areas of unmet medical need including most prominently a lack of any approved drug therapies for the core, defining symptoms of autism. We outline the progress to date in the field of autism drug treatment while taking a future look forward into how decades of work can inform better future steps in this field. En ligne : http://dx.doi.org/10.1007/s10803-021-05237-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=454

Developmental studies in fragile X syndrome / Khaleel A. RAZAK in Journal of Neurodevelopmental Disorders, 12 (2020)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 12 (2020) Titre : Developmental studies in fragile X syndrome Type de document : texte imprimé Auteurs : Khaleel A. RAZAK, Auteur ; Kelli C. DOMINICK, Auteur ; Craig A. ERICKSON, Auteur Langues : Anglais (eng) Mots-clés : Adolescent  Animals  Child  Child, Preschool  Disease Models, Animal  Female  Fragile X Mental Retardation Protein/genetics  Fragile X Syndrome/genetics  Humans  Infant  Male  Mice  Mice, Knockout  Young Adult Index. décimale : PER Périodiques Résumé : Fragile X syndrome (FXS) is the most common single gene cause of autism and intellectual disabilities. Humans with FXS exhibit increased anxiety, sensory hypersensitivity, seizures, repetitive behaviors, cognitive inflexibility, and social behavioral impairments. The main purpose of this review is to summarize developmental studies of FXS in humans and in the mouse model, the Fmr1 knockout mouse. The literature presents considerable evidence that a number of early developmental deficits can be identified and that these early deficits chart a course of altered developmental experience leading to symptoms well characterized in adolescents and adults. Nevertheless, a number of critical issues remain unclear or untested regarding the development of symptomology and underlying mechanisms. First, what is the role of FMRP, the protein product of Fmr1 gene, during different developmental ages? Does the absence of FMRP during early development lead to irreversible changes, or could reintroduction of FMRP or therapeutics aimed at FMRP-interacting proteins/pathways hold promise when provided in adults? These questions have implications for clinical trial designs in terms of optimal treatment windows, but few studies have systematically addressed these issues in preclinical and clinical work. Published studies also point to complex trajectories of symptom development, leading to the conclusion that single developmental time point studies are unlikely to disambiguate effects of genetic mutation from effects of altered developmental experience and compensatory plasticity. We conclude by suggesting a number of experiments needed to address these major gaps in the field. En ligne : https://dx.doi.org/10.1186/s11689-020-09310-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573 [article] Developmental studies in fragile X syndrome [texte imprimé] / Khaleel A. RAZAK, Auteur ; Kelli C. DOMINICK, Auteur ; Craig A. ERICKSON, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 12 (2020) Mots-clés : Adolescent  Animals  Child  Child, Preschool  Disease Models, Animal  Female  Fragile X Mental Retardation Protein/genetics  Fragile X Syndrome/genetics  Humans  Infant  Male  Mice  Mice, Knockout  Young Adult Index. décimale : PER Périodiques Résumé : Fragile X syndrome (FXS) is the most common single gene cause of autism and intellectual disabilities. Humans with FXS exhibit increased anxiety, sensory hypersensitivity, seizures, repetitive behaviors, cognitive inflexibility, and social behavioral impairments. The main purpose of this review is to summarize developmental studies of FXS in humans and in the mouse model, the Fmr1 knockout mouse. The literature presents considerable evidence that a number of early developmental deficits can be identified and that these early deficits chart a course of altered developmental experience leading to symptoms well characterized in adolescents and adults. Nevertheless, a number of critical issues remain unclear or untested regarding the development of symptomology and underlying mechanisms. First, what is the role of FMRP, the protein product of Fmr1 gene, during different developmental ages? Does the absence of FMRP during early development lead to irreversible changes, or could reintroduction of FMRP or therapeutics aimed at FMRP-interacting proteins/pathways hold promise when provided in adults? These questions have implications for clinical trial designs in terms of optimal treatment windows, but few studies have systematically addressed these issues in preclinical and clinical work. Published studies also point to complex trajectories of symptom development, leading to the conclusion that single developmental time point studies are unlikely to disambiguate effects of genetic mutation from effects of altered developmental experience and compensatory plasticity. We conclude by suggesting a number of experiments needed to address these major gaps in the field. En ligne : https://dx.doi.org/10.1186/s11689-020-09310-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573

Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study / Michael P. HONG in Journal of Neurodevelopmental Disorders, 11-1 (December 2019)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 11-1 (December 2019) . - 1 p. Titre : Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study Type de document : texte imprimé Auteurs : Michael P. HONG, Auteur ; Eleanor M. ECKERT, Auteur ; Ernest V. PEDAPATI, Auteur ; Rebecca C. SHAFFER, Auteur ; Kelli C. DOMINICK, Auteur ; Logan K. WINK, Auteur ; John A. SWEENEY, Auteur ; Craig ERICKSON, Auteur Article en page(s) : 1 p. Langues : Anglais (eng) Mots-clés : Autism  Eye tracking  Fragile X syndrome  Gaze aversion  Social anxiety  Social interest Index. décimale : PER Périodiques Résumé : BACKGROUND: Fragile X syndrome (FXS) is the leading inherited cause of autism spectrum disorder, but there remains debate regarding the clinical presentation of social deficits in FXS. The aim of this study was to compare individuals with FXS to typically developing controls (TDC) and individuals with idiopathic autism spectrum disorder (ASD) across two social eye tracking paradigms. METHODS: Individuals with FXS and age- and gender-matched TDC and individuals with idiopathic ASD completed emotional face and social preference eye tracking tasks to evaluate gaze aversion and social interest, respectively. Participants completed a battery of cognitive testing and caregiver-reported measures for neurobehavioral characterization. RESULTS: Individuals with FXS exhibited reduced eye and increased mouth gaze to emotional faces compared to TDC. Gaze aversive findings were found to correlate with measures of anxiety, social communication deficits, and behavioral problems. In the social interest task, while individuals with idiopathic ASD showed significantly less social preference, individuals with FXS displayed social preference similar to TDC. CONCLUSIONS: These findings suggest fragile X syndrome social deficits center on social anxiety without the prominent reduction in social interest associated with autism spectrum disorder. Specifically designed eye tracking techniques clarify the nature of social deficits in fragile X syndrome and may have applications to improve phenotyping and evaluate interventions targeting social functioning impairments. En ligne : http://dx.doi.org/10.1186/s11689-019-9262-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=386 [article] Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study [texte imprimé] / Michael P. HONG, Auteur ; Eleanor M. ECKERT, Auteur ; Ernest V. PEDAPATI, Auteur ; Rebecca C. SHAFFER, Auteur ; Kelli C. DOMINICK, Auteur ; Logan K. WINK, Auteur ; John A. SWEENEY, Auteur ; Craig ERICKSON, Auteur . - 1 p. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 11-1 (December 2019) . - 1 p. Mots-clés : Autism  Eye tracking  Fragile X syndrome  Gaze aversion  Social anxiety  Social interest Index. décimale : PER Périodiques Résumé : BACKGROUND: Fragile X syndrome (FXS) is the leading inherited cause of autism spectrum disorder, but there remains debate regarding the clinical presentation of social deficits in FXS. The aim of this study was to compare individuals with FXS to typically developing controls (TDC) and individuals with idiopathic autism spectrum disorder (ASD) across two social eye tracking paradigms. METHODS: Individuals with FXS and age- and gender-matched TDC and individuals with idiopathic ASD completed emotional face and social preference eye tracking tasks to evaluate gaze aversion and social interest, respectively. Participants completed a battery of cognitive testing and caregiver-reported measures for neurobehavioral characterization. RESULTS: Individuals with FXS exhibited reduced eye and increased mouth gaze to emotional faces compared to TDC. Gaze aversive findings were found to correlate with measures of anxiety, social communication deficits, and behavioral problems. In the social interest task, while individuals with idiopathic ASD showed significantly less social preference, individuals with FXS displayed social preference similar to TDC. CONCLUSIONS: These findings suggest fragile X syndrome social deficits center on social anxiety without the prominent reduction in social interest associated with autism spectrum disorder. Specifically designed eye tracking techniques clarify the nature of social deficits in fragile X syndrome and may have applications to improve phenotyping and evaluate interventions targeting social functioning impairments. En ligne : http://dx.doi.org/10.1186/s11689-019-9262-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=386

Patterns in Medication Use for Treatment of Depression in Autistic Spectrum Disorder / Ernest V. PEDAPATI ; Kelli C. DOMINICK ; Katherine HARRIS ; Martine LAMY ; Cara FOSDICK ; Lauren M. SCHMITT ; Rebecca C. SHAFFER ; Elizabeth SMITH ; Meredith WILL ; Christopher J. MCDOUGLE ; Craig ERICKSON in Journal of Autism and Developmental Disorders, 55-6 (June 2025)  

Permalink

Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome / Sarah E. FITZPATRICK in Journal of Autism and Developmental Disorders, 50-3 (March 2020)  

Permalink

Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis / Eleanor M. ECKERT in Journal of Autism and Developmental Disorders, 49-11 (November 2019)  

Permalink

Specialization of the brain for language in children with Fragile X Syndrome: a functional Near Infrared Spectroscopy study / Elizabeth SMITH in Journal of Neurodevelopmental Disorders, 16 (2024)  

Permalink

---

1 (1 - 9 / 9) Par page : 25 50 100 200